

[Meropenem](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.5. Antituberculosis medicines](#)

ATC codes: [J01DH02](#)

EMLc

Indication

Multi-drug resistant Mycobacterium tuberculosis ICD11 code: [ML32.00](#)

INN

Meropenem

Medicine type

Chemical agent

Antibiotic groups

[WATCH](#)

List type

Core

Additional notes

The square box applies only to the listing of meropenem on the EML.

Formulations

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection ; 1 g in vial (as trihydrate) powder for injection

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

[imipenem + cilastatin](#) (ATC codes: [J01DH51](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Meropenem](#)

DrugBank

[Meropenem](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc.